BCVA: loss of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration
Photodynamic therapy with verteporfin leads to lower loss of 3 or more lines (15 or more letters) visual acuity ETDRS chart compared with photodynamic therapy with 5% dextrose (high certainty).
1 finding from 1 review
Six or more lines visual acuity lost · people with neovascular age‐related macular degeneration
Photodynamic therapy with verteporfin leads to lower loss of 6 or more lines (30 or more letters) visual acuity ETDRS chart compared with photodynamic therapy with 5% dextrose (high certainty).
1 finding from 1 review
Gain of 3 or more lines of visual acuity · people with neovascular age‐related macular degeneration
Photodynamic therapy with verteporfin leads to higher gain of 3 or more lines (15 or more letters) compared with photodynamic therapy with 5% dextrose (high certainty).
1 finding from 1 review
Adverse effects: acute severe visual acuity decrease · people with neovascular age‐related macular degeneration
Photodynamic therapy with verteporfin showed no clear difference in adverse effects: acute severe visual acuity decrease compared with photodynamic therapy with 5% dextrose (moderate certainty).
1 finding from 1 review
Adverse effects: infusion‐related back pain · people with neovascular age‐related macular degeneration
Photodynamic therapy with verteporfin leads to higher adverse effects: infusion‐related back pain compared with photodynamic therapy with 5% dextrose (high certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with neovascular AMD
Radiotherapy showed no clear difference in loss of 3 or more lines of best‐corrected visual acuity Measured… compared with control (low certainty).
1 finding from 1 review
RR 0.82 [0.64, 1.04]
Studies not reported
Low
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Contrast sensitivity (log contrast threshold) Measured using a Pelli‐Robson chart. Higher scores represent better contrast sensitivity. · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Low
New vessel growth Measured using fluorescein angiography or fundus photographs · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Quality of life · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Any adverse outcome · people with neovascular AMD
Radiotherapy may leads to lower any adverse outcome compared with control (low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Number of anti‐VEGF injections · people with neovascular AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Contrast sensitivity (log contrast threshold) Measured using a Pelli‐Robson chart. Higher scores represent better contrast sensitivity. · people with neovascular AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
New vessel growth Measured using fluorescein angiography or fundus photographs · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Quality of life · people with neovascular AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse outcome · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Number of anti‐VEGF injections · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with neovascular AMD
Radiotherapy combined with anti‐VEGF probably leads to higher loss of 3 or more lines of best‐corrected visual acuity Measured… compared with anti‐VEGF alone (moderate certainty).
1 finding from 1 review
RR 2.11 [1.4, 3.17]
Studies not reported
Moderate
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · people with neovascular AMD
Radiotherapy combined with anti‐VEGF showed no clear difference in change in best corrected visual acuity (logMAR units) Measured using… compared with anti‐VEGF alone (low certainty).
1 finding from 1 review
mean difference 0.1
Studies not reported
Low